DOCSLIB.ORG

Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease This PDF is available from The National Academies Press at http://www.nap.edu/catalog.php?record_id=13284 Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease ISBN Committee on a Framework for Development a New Taxonomy of Disease; 978-0-309-22219-8 National Research Council 120 pages 8 1/2 x 11 PAPERBACK (2011) Visit the National Academies Press online and register for... Instant access to free PDF downloads of titles from the NATIONAL ACADEMY OF SCIENCES NATIONAL ACADEMY OF ENGINEERING INSTITUTE OF MEDICINE NATIONAL RESEARCH COUNCIL 10% off print titles Custom notification of new releases in your field of interest Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Request reprint permission for this book Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Committee on A Framework for Developing a New Taxonomy of Disease Board on Life Sciences Division on Earth and Life Studies THE NATIONAL ACADEMIES PRESS Washington, D.C. www.nap.edu PREPUBLICATION COPY Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease PREPUBLICATION COPY Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the Committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This study was supported by Contract/Grant No. N01-0D-4-2139 between the National Academy of Sciences and the National Institutes of Health. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project. Library of Congress Cataloging-in-Publication Data or International Standard Book Number 0-309-0XXXX-X Library of Congress Catalog Card Number 97-XXXXX [Availability from program office as desired.] Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu Copyright 2011 by the National Academy of Sciences. All rights reserved. Printed in the United States of America PREPUBLICATION COPY Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences. The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles M. Vest is president of the National Academy of Engineering. The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine. The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of the National Research Council. www.national-academies.org PREPUBLICATION COPY Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease COMMITTEE ON A FRAMEWORK FOR DEVELOPING A NEW TAXONOMY OF DISEASE SUSAN DESMOND-HELLMANN, (Co-Chair), University of California, San Francisco, CA CHARLES L. SAWYERS, (Co-Chair), Memorial Sloan-Kettering Cancer Center, New York, NY DAVID R. COX, Applied Quantitative Genotherapeutics Unit, Pfizer Inc., San Francisco, CA CLAIRE FRASER-LIGGETT, University of Maryland, School of Medicine, College Park, MD STEPHEN J. GALLI, Stanford University, Stanford, CA DAVID B. GOLDSTEIN, Duke University School of Medicine, Durham, NC DAVID J. HUNTER, The Harvard School of Public Health, Boston, MA ISAAC S. KOHANE, Harvard Medical School, Boston, MA MANUEL LLINAS, Princeton University, Princeton, NJ BERNARD LO, University of California, San Francisco, CA TOM MISTELI, National Cancer Institute, Bethesda, MD SEAN J. MORRISON, University of Texas, Southwestern, TX DAVID G. NICHOLS, The Johns Hopkins University School of Medicine, Baltimore, MD MAYNARD V. OLSON, University of Washington, Seattle, WA CHARMAINE D. ROYAL, Duke University, Durham, NC KEITH R. YAMAMOTO, University of California, San Francisco, CA STAFF INDIA HOOK-BARNARD, Study Director MIRSADA KARALIC-LONCAREVIC, Senior Program Associate AMANDA MAZZAWI, Senior Program Assistant ORIN LUKE, Senior Program Assistant MELINDA DIVITO, Christine Mirzayan Fellow PREPUBLICATION COPY v Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease BOARD ON LIFE SCIENCES KEITH R. YAMAMOTO (Chair), University of California, San Francisco, California BONNIE L. BASSLER, Princeton University, Princeton, NJ VICKI L. CHANDLER, Gordon and Betty Moore Foundation, Palo Alto, California SEAN EDDY, HHMI Janelia Farm Research Campus, Ashburn, VA MARK D. FITZSIMMONS, John D. and Catherine T. MacArthur Foundation, Chicago, IL DAVID R. FRANZ, Midwest Research Institute, Frederick, MD DONALD E. GANEM, Novartis, Emeryville, CA LOUIS J. GROSS, University of Tennessee, Knoxville, TN JO HANDELSMAN, Yale University, New Haven, CT CATO T. LAURENCIN, University of Connecticut Health Center, Farmington, CT BERNARD LO, University of California, San Francisco, CA ROBERT M. NEREM, Georgia Institute of Technology, Atlanta, GA CAMILLE PARMESAN, University of Texas, Austin, TX MURIEL E. POSTON, Skidmore College, Saratoga Springs, NY ALISON G. POWER, Cornell University, Ithaca, NY BRUCE W. STILLMAN, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY CYNTHIA WOLBERGER, Johns Hopkins University School of Medicine, Baltimore, MD MARY WOOLLEY, Research!America, Alexandria, VA STAFF FRANCES E. SHARPLES, Director JO L. HUSBANDS, Scholar/Senior Project Director JAY B. LABOV, Senior Scientist/Program Director for Biology Education KATHERINE BOWMAN, Senior Program Officer MARILEE K. SHELTON-DAVENPORT, Senior Program Officer INDIA HOOK-BARNARD, Program Officer KEEGAN SAWYER, Program Officer ANNA FARRAR, Financial Associate CARL-GUSTAV ANDERSON, Program Associate ORIN LUKE, Senior Program Assistant AMANDA MAZZAWI, Senior Program Assistant SAYYEDA AYESHA AHMED, Senior Program Assistant vi PREPUBLICATION COPY Copyright © National Academy of Sciences. All rights reserved. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease ACKNOWLEDGEMENTS This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise in accordance with procedures approved
Load more

Recommended publications
  • Integrative Analysis of Exogenous, Endogenous, Tumour and Immune
    Gut Online First, published on February 6, 2018 as 10.1136/gutjnl-2017-315537 Recent advances in basic science Integrative analysis of exogenous, endogenous, Gut: first published as 10.1136/gutjnl-2017-315537 on 6 February 2018. Downloaded from tumour and immune factors for precision medicine Shuji Ogino,1,2,3,4 Jonathan A Nowak,1 Tsuyoshi Hamada,2 Amanda I Phipps,5,6 Ulrike Peters,5,6 Danny A Milner Jr,7 Edward L Giovannucci,3,8,9 Reiko Nishihara,1,3,4,8,10 Marios Giannakis,4,11,12 Wendy S Garrett,4,11,13 Mingyang Song8,14,15 For numbered affiliations see ABSTRACT including inflammatory and immune cells. A fraction end of article. Immunotherapy strategies targeting immune checkpoints of somatic mutations may result in the generation of such as the CTLA4 and CD274 (programmed cell death new antigens (neoantigens) that can be recognised as Correspondence to 1 ligand 1, PD-L1)/PDCD1 (programmed cell death 1, non-self by the immune system. During an individu- Dr Shuji Ogino, Program in MPE Molecular Pathological PD-1) T-cell coreceptor pathways are revolutionising al's life-course, cells may acquire somatic molecular Epidemiology, Brigham and oncology. The approval of pembrolizumab use for alterations, and some of these cells undergo clonal Women’s Hospital, Boston, MA solid tumours with high-level microsatellite instability expansion, displaying hallmarks of early neoplasia. 02215, USA; shuji_ ogino@ dfci. or mismatch repair deficiency by the US Food and Many of these cells are likely kept in check or killed harvard. edu Drug Administration highlights promise of precision by the host immune system before they can develop Received 24 October 2017 immuno-oncology.
    [Show full text]
  • Rare Variant Contribution to Human Disease in 281,104 UK Biobank Exomes W ­ 1,19 1,19 2,19 2 2 Quanli Wang , Ryan S
    https://doi.org/10.1038/s41586-021-03855-y Accelerated Article Preview Rare variant contribution to human disease W in 281,104 UK Biobank exomes E VI Received: 3 November 2020 Quanli Wang, Ryan S. Dhindsa, Keren Carss, Andrew R. Harper, Abhishek N ag­­, I oa nn a Tachmazidou, Dimitrios Vitsios, Sri V. V. Deevi, Alex Mackay, EDaniel Muthas, Accepted: 28 July 2021 Michael Hühn, Sue Monkley, Henric O ls so n , S eb astian Wasilewski, Katherine R. Smith, Accelerated Article Preview Published Ruth March, Adam Platt, Carolina Haefliger & Slavé PetrovskiR online 10 August 2021 P Cite this article as: Wang, Q. et al. Rare variant This is a PDF fle of a peer-reviewed paper that has been accepted for publication. contribution to human disease in 281,104 UK Biobank exomes. Nature https:// Although unedited, the content has been subjectedE to preliminary formatting. Nature doi.org/10.1038/s41586-021-03855-y (2021). is providing this early version of the typeset paper as a service to our authors and Open access readers. The text and fgures will undergoL copyediting and a proof review before the paper is published in its fnal form. Please note that during the production process errors may be discovered which Ccould afect the content, and all legal disclaimers apply. TI R A D E T A R E L E C C A Nature | www.nature.com Article Rare variant contribution to human disease in 281,104 UK Biobank exomes W 1,19 1,19 2,19 2 2 https://doi.org/10.1038/s41586-021-03855-y Quanli Wang , Ryan S.
    [Show full text]
  • The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The
    Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure ​ for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). ​ ​ Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences ​ 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that ​ ​ mention Core Data Resource by name or include specific data record accession numbers.
    [Show full text]
  • Pomona College Magazine Fall/Winter 2020: the New (Ab
    INSIDE:THE NEW COLLEGE MAGAZINE (AB)NORMAL • The Economy • Childcare • City Life • Dating • Education • Movies • Elections Fall-Winter 2020 • Etiquette • Food • Housing •Religion • Sports • Tourism • Transportation • Work & more Nobel Laureate Jennifer Doudna ’85 HOMEPAGE Together in Cyberspace With the College closed for the fall semester and all instruction temporarily online, Pomona faculty have relied on a range of technologies to teach their classes and build community among their students. At top left, Chemistry Professor Jane Liu conducts a Zoom class in Biochemistry from her office in Seaver North. At bottom left, Theatre Professor Giovanni Molina Ortega accompanies students in his Musical Theatre class from a piano in Seaver Theatre. At far right, German Professor Hans Rindesbacher puts a group of beginning German students through their paces from his office in Mason Hall. —Photos by Jeff Hing STRAY THOUGHTS COLLEGE MAGAZINE Pomona Jennifer Doudna ’85 FALL/WINTER 2020 • VOLUME 56, NO. 3 2020 Nobel Prize in Chemistry The New Abnormal EDITOR/DESIGNER Mark Wood ([email protected]) e’re shaped by the crises of our times—especially those that happen when ASSISTANT EDITOR The Prize Wwe’re young. Looking back on my parents’ lives with the relative wisdom of Robyn Norwood ([email protected]) Jennifer Doudna ’85 shares the 2020 age, I can see the currents that carried them, turning them into the people I knew. Nobel Prize in Chemistry for her work with They were both children of the Great Depression, and the marks of that experi- BOOK EDITOR the CRISPR-Cas9 molecular scissors. Sneha Abraham ([email protected]) ence were stamped into their psyches in ways that seem obvious to me now.
    [Show full text]
  • The Future of Precision Medicine : Potential Impacts for Health Technology Assessment
    This is a repository copy of The Future of Precision Medicine : Potential Impacts for Health Technology Assessment. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/133069/ Version: Accepted Version Article: Love-Koh, James orcid.org/0000-0001-9009-5346, Peel, Alison, Rejon-Parilla, Juan Carlos et al. (6 more authors) (2018) The Future of Precision Medicine : Potential Impacts for Health Technology Assessment. Pharmacoeconomics. pp. 1439-1451. ISSN 1179-2027 https://doi.org/10.1007/s40273-018-0686-6 Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative works on the same terms. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ The Future of Precision Medicine: Potential Impacts for Health Technology Assessment Title: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment Authors: James Love-Koh1,2, Alison Peel1, Juan Carlos Rejon-Parilla3, Kate Ennis1,4, Rosemary Lovett3, Andrea Manca2,5, Anastasia Chalkidou6, Hannah Wood1, Matthew Taylor1 1 YorK Health Economics Consortium 2 Centre for Health Economics, University of YorK 3 National Institute for Health and Care Excellence 4 Institute of Infection and Global Health, University of Liverpool 5 Luxembourg Institute of Health 6 Kings Technology Evaluation Centre Corresponding Author Details: Name: James Love-Koh Address: Centre for Health Economics, Alcuin A Block, University of York, Heslington, York, YO10 5DD, UK.
    [Show full text]
  • Open Targets Genetics
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Open Targets Genetics: An open approach to systematically prioritize causal variants 2 and genes at all published GWAS trait-associated loci 3 4 Edward Mountjoy1,2, Ellen M. Schmidt1,2, Miguel Carmona2,3, Gareth Peat2,3, Alfredo Miranda2,3, 5 Luca Fumis2,3, James Hayhurst2,3, Annalisa Buniello2,3, Jeremy Schwartzentruber1,2,3, Mohd 6 Anisul Karim1,2, Daniel Wright1,2, Andrew Hercules2,3, Eliseo Papa4, Eric Fauman5, Jeffrey C. 7 Barrett1,2, John A. Todd6, David Ochoa2,3, Ian Dunham1,2,3, Maya Ghoussaini1,2,*. 8 9 1. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 10 1SA, UK 11 2. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 12 3. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 13 Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK 14 4. Systems Biology, Biogen, Cambridge, MA, 02142, United States 15 5. Integrative Biology, Internal Medicine Research Unit, Pfizer Worldwide Research, 16 Development and Medical, Cambridge, MA 02139, United States 17 6. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford 18 Biomedical Research Centre, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, 19 UK 20 * Corresponding author 21 22 23 24 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.16.299271; this version posted September 17, 2020.
    [Show full text]
  • Select Committee on Science and Technology Corrected Oral Evidence: Ageing: Science, Technology and Healthy Living
    Select Committee on Science and Technology Corrected oral evidence: Ageing: science, technology and healthy living Tuesday 25 February 2020 10.20 am Watch the meeting Members present: Lord Patel (The Chair); Lord Borwick; Lord Browne of Ladyton; Baroness Hilton of Eggardon; Lord Kakkar; Lord Mair; Baroness Manningham-Buller; Baroness Penn; Viscount Ridley; Baroness Rock; Baroness Sheehan; Baroness Walmsley; Lord Winston; Baroness Young of Old Scone. Evidence Session No. 15 Heard in Public Questions 131 - 138 Witnesses Dame Fiona Caldicott, National Data Guardian; Matthew Gould, CEO, NHSX; Chris Roebuck, Chief Statistician, NHS Digital; Dr Jem Rashbass, Executive Director of Master Registries and Data, NHS Digital. USE OF THE TRANSCRIPT This is a corrected transcript of evidence taken in public and webcast on www.parliamentlive.tv. 1 Examination of witnesses Dame Fiona Caldicott, Matthew Gould, Chris Roebuck and Dr Jem Rashbass. Q131 The Chair: Good morning, Dame Fiona and gentlemen. Welcome and thank you for coming today to help us with this inquiry. There are some familiar faces to me; it is nice to see you. Before we start, would you mind introducing yourselves for the record from my left? If you want to make an opening statement, feel free to do so. If you have any interests to declare, please do so at the beginning. Chris Roebuck: I am the chief statistician at NHS Digital. I am accountable for the nearly 300 sets of official statistics we produce each year. These cover a range of health and care data, predominantly in England, including administrative data, clinical data and survey data. We release them to encourage transparency, to help with local and national decision-making and for public accountability.
    [Show full text]
  • GSA Welcomes 2012 Board Members
    7INTERs3PRING 4HE'3!2EPORTER winter s spring 2012 New Executive GSA Welcomes 2012 Board Members Director Now on Board The Genetics Society of America New Members of the GSA Board of welcomes four new members elected Directors Adam P. Fagen, by the general membership to the Ph.D., stepped in as 2012 GSA Board of Directors. The VICE PRESIDENT: GSA’s new Executive new members are: Michael Lynch Michael Lynch, Director beginning (Indiana University), who serves as Distinguished December 1, 2011. vice president in 2012 and as GSA Professor of Dr. Fagen previously president in 2013 and Marnie E. Biology, Class of was at the American Halpern (Carnegie Institution for 1954 Professor, Society of Plant Science); Mohamed Noor (Duke Department of Biologists (ASPB), University); and John Schimenti Biology, Indiana where he was the director of public (Cornell University), who will serve as University, continued on page nineteen directors. Bloomington. Dr. Lynch is a population and evolutionary biologist and a In addition to these elected officers, long-time member of GSA. Dr. Lynch 2012 Brenda J. Andrews (University of sees GSA as the home for geneticists Toronto), Editor-in-Chief of GSA’s who study a broad base of topics GSA Award journal, G3: Genes|Genomes|Genetics, and organisms, and as a forum Recipients which was first published online in where general discussion occurs, June 2011, becomes a member of the whether based on the principles Announced Board of Directors. The bylaws have of genetics, the most pressing historically included the GENETICS GSA is pleased to announce the issues within the discipline itself, or editor-in-chief on the Board and as a responses to societal concerns and/ 2012 recipients of its five awards result of a 2011 bylaw revision, the G3 for distinguished service in the or conflicts within applied genetics.
    [Show full text]
  • Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I
    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.
    [Show full text]
  • David Botstein 2015 Book.Pdf
    Princeton University HONORS FACULTY MEMBERS RECEIVING EMERITUS STATUS May 2015 The biographical sketches were written by colleagues in the departments of those honored. Copyright © 2015 by The Trustees of Princeton University 550275 Contents Faculty Members Receiving Emeritus Status 2015 Steven L. Bernasek .......................3 David Botstein...........................6 Erhan Çinlar ............................8 Caryl Emerson.......................... 11 Christodoulos A. Floudas ................. 15 James L. Gould ......................... 17 Edward John Groth III ...................20 Philip John Holmes ......................23 Paul R. Krugman .......................27 Bede Liu .............................. 31 Alan Eugene Mann ......................33 Joyce Carol Oates .......................36 Clarence Ernest Schutt ...................39 Lee Merrill Silver .......................41 Thomas James Trussell ...................43 Sigurd Wagner .........................46 { 1 } { 2 } David Botstein avid Botstein was educated at Harvard (A.B. 1963) and the D University of Michigan (Ph.D. 1967). He joined the faculty of the Massachusetts Institute of Technology, rising through the ranks from instructor to professor of genetics. In 1987, he moved to Genentech, Inc. as vice president–science, and, in 1990, he joined Stanford University’s School of Medicine, where he was chairman of the Department of Genetics. In July, 2003 he became director of the Lewis-Sigler Institute for Integrative Genomics and the Anthony B. Evnin ’62 Professor of Genomics at Princeton University. David’s research has centered on genetics, especially the use of genetic methods to understand biological functions. His early work in bacterial genetics contributed to the discovery of transposable elements in bacteria and an understanding of their physical structures and genetic properties. In the early 1970s, he turned to budding yeast (Saccharomyces cerevisiae) and devised novel genetic methods to study the functions of the actin and tubulin cytoskeletons.
    [Show full text]
  • What Are Precision Medicine and Personalized Medicine?
    What Are Precision Medicine and Personalized Medicine? Precision medicine, also known as personalized medicine, is a new frontier for healthcare combining genomics, big data analytics, and population health. Source: Thinkstock Since the beginning of recorded history, healthcare practitioners have striven to make their actions more effective for their patients by experimenting with different treatments, observing and sharing their results, and improving upon the efforts of previous generations. Becoming more accurate, precise, proactive, and impactful for each individual that comes under their care has always been the goal of all clinicians, no matter how basic the tools at their disposal. But now, modern physicians and scientists are now able to take this mission far, far beyond the reach of their ancestors with the help of electronic health records, genetic testing, big data analytics, and supercomputing – all the ingredients required to engage in what is quickly becoming truly precise and personalized medicine. Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackling diseases that have thus far eluded effective treatments or cures. Cancer, neurodegenerative diseases, and rare genetic conditions take an enormous toll on individuals, families and societies as a whole. Approximately 1.7 million new cancer cases were diagnosed in the United States in 2017. Around 600,000 deaths were expected during that year, according to the American Cancer Society. The Agency for Healthcare Research and Quality adds that the direct economic impact of cancer is around $80 billion per year – loss of productivity, wages, and caregiver needs sap billions more from the economy.
    [Show full text]
  • Advancing Standards for Precision Medicine
    Advancing Standards for Precision Medicine FINAL REPORT Prepared by: Audacious Inquiry on behalf of the Office of the National Coordinator for Health Information Technology under Contract No. HHSM-500-2017-000101 Task Order No. HHSP23320100013U January 2021 ONC Advancing Standards for Precision Medicine Table of Contents Executive Summary ...................................................................................................................................... 5 Standards Development and Demonstration Projects ............................................................................ 5 Mobile Health, Sensors, and Wearables ........................................................................................... 5 Social Determinants of Health (SDOH) ............................................................................................. 5 Findings and Lessons Learned .......................................................................................................... 6 Recommendations ........................................................................................................................................ 6 Introduction ................................................................................................................................................... 7 Background ................................................................................................................................................... 7 Project Purpose, Goals, and Objectives ..................................................................................................
    [Show full text]